UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Nature reviews. Neurology, ISSN 1759-4758, 12/2010, Volume 6, Issue 12, pp. 657 - 666
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Peripheral Nervous System Diseases - therapy | Peripheral Nervous System Diseases - chemically induced | Antineoplastic Agents - adverse effects | Humans | Neoplasms - drug therapy | Drugs | Nervous system diseases | Chemotherapy | Diagnosis | Research | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4785 - 4794
cisplatin-based chemotherapy | ghrelin | appetite | esophageal cancer | food intake | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Tumors | Esophagus | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Ghrelin - administration & dosage | Prospective Studies | Nausea - chemically induced | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Esophageal Neoplasms - pathology | Patient Selection | Adult | Female | Surveys and Questionnaires | Vomiting - prevention & control | Ghrelin - therapeutic use | Appetite - drug effects | Treatment Outcome | Energy Intake - drug effects | Carcinoma, Squamous Cell - physiopathology | Nausea - prevention & control | Vomiting - chemically induced | Carcinoma, Squamous Cell - drug therapy | Neoadjuvant Therapy - methods | Cisplatin - adverse effects | Esophageal Neoplasms - physiopathology | Quality of Life | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Chemotherapy | Usage | Care and treatment | Ghrelin | Research | Esophageal cancer | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 12/2020, Volume 147, Issue 11, pp. 3189 - 3198
cisplatin‐based chemotherapy | testicular cancer | high‐intensity training | thromboembolic events | cisplatin-based chemotherapy | high-intensity training | Life Sciences & Biomedicine | Oncology | Science & Technology | Oncology, Experimental | Research | Metastasis | Antineoplastic agents | Testicular cancer | Antimitotic agents | Pulmonary embolism | Chemotherapy | Heart beat | Weight training | Exercise therapy | Thromboembolism | Cancer | Myocardial infarction | Physical training | Case reports | Cisplatin | Embolism | Metastases | Literature reviews | Heart rate | Physical fitness | Exercise | Cardiorespiratory fitness | Testes | Index Medicus
Journal Article
Journal of cellular biochemistry, ISSN 0730-2312, 03/2019, Volume 120, Issue 3, pp. 3547 - 3558
nasopharyngeal carcinoma (NPC) | NEK2 | cisplatin‐based chemotherapy resistance | cisplatin-based chemotherapy resistance | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Immunohistochemistry | Cell survival | Nek2 protein | Pathogenesis | Xenotransplantation | Ribonucleic acid--RNA | Survival | Cisplatin | Proteins | Nasopharyngeal carcinoma | Chemotherapy | Medical prognosis | Xenografts | Biomarkers | Index Medicus | s
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4785 - 4794
Journal Article
Acta obstetricia et gynecologica Scandinavica, ISSN 0001-6349, 02/2019, Volume 98, Issue 2, pp. 240 - 249
cisplatin‐based chemotherapy | peripheral paresthesia | neuropathy | Raynaud's phenomenon | malignant ovarian germ cell tumors | cisplatin-based chemotherapy | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Neurotoxicity | Chemotherapy | Side effects | Raynaud disease | Womens health | Ovarian cancer | Quantitative analysis | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 01/2012, Volume 118, Issue 2, pp. 358 - 364
cisplatin‐based chemotherapy | neoadjuvant chemotherapy | adjuvant chemotherapy | systemic chemotherapy | muscle‐invasive bladder cancer | locally advanced bladder cancer | Neoadjuvant chemotherapy | Adjuvant chemotherapy | Muscle-invasive bladder cancer | Locally advanced bladder cancer | Cisplatin-based chemotherapy | Systemic chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the urinary system | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Tumors | Urinary Bladder Neoplasms - mortality | Humans | Middle Aged | Carboplatin - administration & dosage | Male | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Cisplatin - administration & dosage | Cystectomy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Urinary Bladder Neoplasms - pathology | Female | Neoadjuvant Therapy | Aged | Retrospective Studies | Chemotherapy, Adjuvant | Neoadjuvant therapy | Care and treatment | Patient outcomes | Adjuvant treatment | Research | Bladder cancer | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Gynecologic oncology, ISSN 0090-8258, 2007, Volume 108, Issue 1, pp. 226 - 233
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Adjuvant radiotherapy | Adjuvant chemotherapy | Endometrial cancer | Cisplatin-based chemotherapy | Intermediate risk | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Endometrial Neoplasms - radiotherapy | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Female | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Adenocarcinoma - radiotherapy | Doxorubicin - administration & dosage | Risk Factors | Treatment Outcome | Adenocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - surgery | Cisplatin - adverse effects | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Patient Compliance | Neoplasm Staging | Doxorubicin - adverse effects | Adenocarcinoma - surgery | Care and treatment | Chemotherapy | Oncology, Experimental | Clinical trials | Research | Radiotherapy | Cancer | Index Medicus
Journal Article
Clinical lung cancer, ISSN 1525-7304, 2017, Volume 19, Issue 1, pp. 58 - 64
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | NCCN guidelines | Tumor genetic profile | Prognostic genetic signature | Cisplatin-based adjuvant therapy | Risk stratification | NCCN guidelines | Tumor genetic profile | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Predictive Value of Tests | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Male | Risk | Carcinoma, Non-Small-Cell Lung - mortality | Drug Resistance, Neoplasm - genetics | Survival Analysis | Pathology, Molecular - methods | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy, Adjuvant | Neoplasm Staging | Practice Guidelines as Topic | Index Medicus
Journal Article